Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke

Neurology. 2007 Mar 27;68(13):1020-4. doi: 10.1212/01.wnl.0000257817.29883.48.

Abstract

Objectives: To evaluate whether the presence of leukoaraiosis or multiple lacunes is associated with symptomatic intracerebral hemorrhage (ICH) and 90-day outcome after thrombolytic treatment with tissue plasminogen activator (tPA).

Methods: Data were from a Canadian national registry of thrombolyzed patients with ischemic stroke. A total of 820 scans were assessed, blind to clinical features, for the presence of severe vs no/moderate leukoaraiosis, and of multiple (>2) vs no/single lacunar infarcts. Logistic regression was used to determine if an independent interaction existed between the presence and degree of leukoaraiosis/lacunes and risk of symptomatic ICH, and to evaluate the predictive role of leukoaraiosis and lacunes in relation to 90-day outcome.

Results: An overall symptomatic ICH rate of 3.5% was observed. The rate of symptomatic ICH increased up to 10% in patients with severe leukoaraiosis and multiple lacunes. A significant association was observed between ICH risk and either severe leukoaraiosis (RR = 2.7 [95% CI 1.1 to 6.5]) or multiple lacunes (RR = 3.4 [95% CI 1.5 to 7.6]). Patients with multiple lacunes, but not leukoaraiosis, had higher mortality at 90 days compared to those with one or no lacunes (OR = 2.9, 95% CI 1.3 to 6.2, p = 0.008). No difference was observed in the good outcome rate among patients with and without leukoaraiosis or lacunes or both.

Conclusion: The presence of small vessel disease on CT scan does not affect overall clinical outcome at 3 months in routine community use of tPA for ischemic stroke. A significant increase in the risk of symptomatic ICH is observed.

MeSH terms

  • Acute Disease / therapy
  • Aged
  • Brain / blood supply
  • Brain / drug effects
  • Brain / physiopathology
  • Brain Infarction / complications
  • Brain Infarction / pathology
  • Brain Infarction / physiopathology
  • Brain Ischemia / complications
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / physiopathology
  • Canada
  • Cerebral Arteries / drug effects
  • Cerebral Arteries / pathology
  • Cerebral Arteries / physiopathology
  • Cerebral Hemorrhage / chemically induced*
  • Cerebral Hemorrhage / pathology
  • Cerebral Hemorrhage / physiopathology
  • Cohort Studies
  • Female
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Leukoaraiosis / complications*
  • Leukoaraiosis / pathology
  • Leukoaraiosis / physiopathology
  • Male
  • Nerve Fibers, Myelinated / pathology
  • Prospective Studies
  • Retrospective Studies
  • Risk Factors
  • Stroke / complications
  • Stroke / drug therapy*
  • Stroke / physiopathology
  • Thrombolytic Therapy / adverse effects*
  • Tissue Plasminogen Activator / adverse effects*

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator